Journal List > Korean J Sports Med > v.34(1) > 1054581

Seo, Sung, and Park: The Effect of Individualized Exercise Parameters Applied to Two Patients Recovering from Implanted Left Ventricular Assist Devices in Korea

Abstract

Left ventricular assist devices (LVADs) are a treatment option for patients with severe chronic heart failure. These patients are referred to an inpatient cardiac rehabilitation after implantation to improve an aerobic capacity and quality of life (QOL). Several studies have reported that an exercise therapy, which is a component of cardiac rehabilitation, improves exercise capacity and QOL. The LVADs were implanted successfully in a destination therapy in two Korean patients, and these patients were enrolled in the cardiac rehabilitation. After an individualized intervention, they were discharged from improved exercise functional capacity and QOL. This is the first report showing a benefit of the individualized exercise therapy using different parameters after LVADs implantation in Korea.

REFERENCES

1.Roger VL., Go AS., Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics— 2012 update: a report from the American Heart Association. Circulation. 2012. 125:188–97.
2.Ministry of Health and Welfare. Ministry of health and welfare statistical year book 2013 [Internet]. Sejong (KR): Ministry of Health and Welfare; [cited 2016 May 1]. Available from:. http://stat.mohw.go.kr/front/statData/mohwAnnalsWpView.jsp?menuId=14&bbsSeq=1&nttSeq=21132&nttClsCd=01&searchKey=&searchWord=&nPage=1.
3.Slaughter MS., Rogers JG., Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009. 361:2241–51.
crossref
4.Hayes K., Leet AS., Bradley SJ., Holland AE. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary randomized controlled trial. J Heart Lung Transplant. 2012. 31:729–34.
crossref
5.Ueno A., Tomizawa Y. Cardiac rehabilitation and artificial heart devices. J Artif Organs. 2009. 12:90–7.
crossref
6.Scheiderer R., Belden C., Schwab D., Haney C., Paz J. Exercise guidelines for inpatients following ventricular assist device placement: a systematic review of the literature. Cardiopulm Phys Ther J. 2013. 24:35–42.
crossref
7.Maciver J., Ross HJ. Quality of life and left ventricular assist device support. Circulation. 2012. 126:866–74.
crossref
8.Wells CL. Physical therapist management of patients with ventricular assist devices: key considerations for the acute care physical therapist. Phys Ther. 2013. 93:266–78.
crossref
9.Ross RM., Murthy JN., Wollak ID., Jackson AS. The six minute walk test accurately estimates mean peak oxygen uptake. BMC Pulm Med. 2010. 10:31.
crossref
10.Kirklin JK., Naftel DC., Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011. 30:115–23.
crossref

Fig. 1.
Chest X-ray view after implantation. The successful implantation of the continuous flow left ventricular assist device (HeartMate II) was showed in the figure. First case (A), second case (B).
kjsm-34-78f1.tif
Fig. 2.
The 6-minute walk test results for the patients (bar). There was improvement to walk distance in our cases. It means that these patients were improved exercise capacity after the intervention. Pre: pre-rehabilitation, Post: post-rehabilitation.
kjsm-34-78f2.tif
Fig. 3.
Minnesota Living with Heart Failure Questionnaire (MLHFQ) score was showed. All scores of post-rehabilitation (Post) were decreased that means quality of life was improved relative to pre-rehabilitation (Pre). First case (A), second case (B).
kjsm-34-78f3.tif
Table 1.
Demographic data for patients
Characteristics Case A Case B
Sex Male Male
Age (yr) 76 66
Height (cm)/weight (kg) 167/50 164/63
Blood pressure (mm Hg) 93/57 76/48
Heart rate (bpm) 99 81
Body mass index (kg/m2) 21.3 23.1
Diagnosis Systolic heart failure Ischemic cardiomyopathy
LVEF (%) 20.0 22.3
NYHA class II III
Medication Spironolactone 25 mg, Furosemide 40 mg, Furosemide 40 mg,
Amiodarone 100 mg, Cilostazole 50 mg, Cefixime 200 mg,
Clonazepam 0.6 mg, Isosorbide mono 20 mg , Beszyme,
Warfarin 2 mg, Loperamide oxide, Lactulose syrup 15 mL,
Enoxaparin 60 mg Cough syrup 20 mL
Echocardiogram Markedly LV dilation with severe Ischemic heart disease with severe
LV systolic dysfunction LV systolic dysfunction
Moderate TR Dilated LV
Mild MR Dilated RV with decrease RV dysfunction
Both atrial enlargement Mild MR
Dilated aortic root (43 mm) & Mild AR
ascending aorta (39 mm) Diastolic dysfunction grade 3
  with LV filling pressure
  Both atrial enlargement

LVEF: left ventricular ejection fraction, NYHA: New York Heart Association, LV: left ventricle, TR: tricuspid regurgitation, MR: mitral regurgitation, RV: right ventricle, AR: aortic regurgitation.

Table 2.
Clinical exercise data for exercise intervention
Variable Case A Case B
Initial time of rehabilitation POD 3 POD 3
Transferred to the ward POD 10 POD 10
Exercise frequency 5/wk 5/wk
Exercise intensity Target HR+30 bpm: 109 bpm Target HR+30 bpm: 118 bpm
  RPE: 11−14 is more suitable RPE: 11−14
  or modified Borg scale (3−5)  
Exercise time (min/day) 30−60 30−60
ICU walking POD 5 POD 5
Corridor walking POD 10 POD 10
Step up and down POD 27 POD 18
Stationary bike POD 19 (level 0−1) POD 19 (level 0−1)
Treadmill POD 90 (speed 2.7 km/hr, grade 2) POD 26 (speed 4.0 km/hr, grade 2)
Postoperative complication Aspiration pneumonia, Post OP bleeding tendency → massive
  delayed wound healing, NSVT transfusion, hematoma or effusion,
    LVAD site hematoma (+)
LOS in the ICU (day) 10 10
LOS in the ward (day) 126 29

POD: postoperative day, HR: heart rate, RPE: rating of perceived exertion, ICU: intensive care unit, NSVT: non sustain ventricular tachycardia, OP: operation, LVAD: left ventricular assist device, LOS: length of stay.

TOOLS
Similar articles